NYSE:LLY 15 December 2025 - 25 December 2025

Eli Lilly shares closed at $1,071.44 on Dec. 19, near record highs, as new late-stage data for oral GLP-1 candidate orforglipron showed less weight regain versus placebo after switching from injectables. Retatrutide posted 28.7% average weight loss in a Phase 3 trial. Lilly cut Zepbound prices in the U.S. and Canada. Orforglipron could receive FDA approval as early as March 2026.

Eli Lilly shares closed at $1,071.44 on Friday, Dec. 19, up 4.3% from the previous week. The company’s stock remains near record highs as late-stage trial data showed its oral obesity drug orforglipron helped patients maintain weight loss after switching from injectables. Reuters reported the FDA is considering a faster review timeline for orforglipron.

Eli Lilly reported positive Phase 3 results for its oral obesity drug orforglipron, showing patients maintained prior weight loss after switching from injectable treatments. Shares rose about 1.75% to $1,060 on Thursday. The company also plans significant price cuts for Mounjaro and Zepbound in Canada, according to a separate report. Lilly said orforglipron’s safety profile matched earlier studies, with mostly mild gastrointestinal side effects.

Eli Lilly shares closed Dec. 17 at $1,041.79, down 1.2%, and held steady after hours. Trading volume reached 3.6 million shares. The move came as investors weighed U.S. drug-pricing talks and sector rotation into healthcare. Broader markets fell, with the S&P 500 down 1.2%.

Eli Lilly shares traded near $1,050 on Dec. 16, 2025, after a year in which the company became the first drugmaker to hit a $1 trillion market value. Daiwa upgraded the stock to Buy and raised its price target to $1,230. Lilly cut prices on Zepbound vials this month to expand access, prompting debate over future margins as competition grows.

Eli Lilly shares rose about 2% to $1,048.47 in early trading Monday after new Phase 3 data showed retatrutide led to nearly 29% weight loss in patients with obesity and knee osteoarthritis. Bank of America trimmed its price target on LLY to $1,268 but kept a “buy” rating. Investors are also watching FDA review timing for orforglipron and ongoing U.S. capacity expansion.